FY-21

• UNSPSC Description:

  FY-21 is a selective inhibitor of LSD1 (IC50=340 nM), with anti-proliferation and anti-colony formation activities. FY-21 enhances p53 expression, down-regulates HOXA9 and MEIS1 expression. FY-21 also induces leukemia cell differentiation to exhibts antitumor activity[1].

• Target Antigen:

  Histone Demethylase

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/fy-21.html

• Solubility:

  10 mM in DMSO

• Smiles:

  OC1=C(C=C2C(NCCC2=C1)C3=CC=C(C=C3)[N+]([O-])=O)O.FC(C(O)=O)(F)F

• Molecular Weight:

  400.31

• References & Citations:

  [1]Yang C, et al. Discovery of new tetrahydroisoquinolines as potent and selective LSD1 inhibitors for the treatment of MLL-rearranged leukemia. Eur J Med Chem. 2023 Sep 5;257:115516.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3049681-20-8